Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial
Launched by THE UNIVERSITY OF QUEENSLAND · Jun 10, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether using a special cap containing chlorhexidine (an antimicrobial solution) on hemodialysis catheters can help prevent infections compared to the standard cap currently in use. Hemodialysis is a treatment for kidney failure that often requires a catheter, which can sometimes lead to serious infections. By comparing the two types of caps, the researchers hope to find out if the chlorhexidine cap reduces the risk of infections related to these catheters.
To participate in the trial, you need to be at least 18 years old, able to give your consent, and have kidney failure that requires hemodialysis. You should also have been free from certain infections for at least 21 days and not have any allergies to chlorhexidine or the materials used in the caps. If you join, you will be randomly assigned to receive either the standard cap or the chlorhexidine cap, and the researchers will monitor you for any infections that may occur during the study. This trial is still in the planning stages and has not yet begun recruiting participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age≥18
- • Able to provide informed consent
- • Kidney failure requiring a tunnelled CVC for treatment (haemodialysis)
- • 21 days BSI free
- • No known allergy to chlorhexidine and/or nylon and/or polypropylene.
- Exclusion Criteria:
- • Current CLABSI
- • Known allergic to chlorhexidine and/or nylon and/or polypropylene.
- • Patients on an end-of-life pathway
- • People with a cognitive impairment and/or intellectual disability
About The University Of Queensland
The University of Queensland (UQ) is a leading research institution located in Australia, renowned for its commitment to advancing health and medical knowledge through innovative clinical trials. With a strong emphasis on collaboration between academia, industry, and healthcare communities, UQ leverages its extensive resources and expertise to conduct high-quality research aimed at improving patient outcomes. The university's multidisciplinary approach facilitates the exploration of diverse therapeutic areas, ensuring rigorous scientific methodologies and adherence to ethical standards. UQ's dedication to fostering a culture of discovery positions it at the forefront of clinical research, contributing significantly to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Herston, Queensland, Australia
Patients applied
Trial Officials
Claire Rickard
Principal Investigator
The University of Queensland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported